

December 21, 2023

The Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400001
BSE Scrip Code: 543427

The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C/1, G Block,
Bandra - Kurla Complex
Bandra (East), Mumbai – 400051
NSE Symbol: MEDPLUS

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")

Pursuant to Regulation 30, read with Clause 20 Para A of Part A of Schedule III, of SEBI Listing Regulations, we would like to inform that one of our Subsidiary Company has received an order from Drugs and Control Authority. The detailed disclosure with respect to the order as required under the SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13 July 2023 is enclosed herewith as per "Annexure A"

The aforesaid information is also being placed on the website of the Company at www.medplusindia.com

Kindly take the same on records.

For MedPlus Health Services Limited

Manoj Kumar Srivastava
Company Secretary & Compliance Officer
FCS 7460

Encl. Annexure A



Annexure A

Details required under the Listing Regulations read with SEBI Circular SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated 13 July 2023

Sr. No.	Name(s) of the Authority	Nature and details of the action(s) taken, initiated or order(s) passed	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	Details of the violation(s)/ contravention(s) committed or alleged to be committed
1	Assistant Director & Drug Sales licencing authority, Drug Control administration, Rangareddy District, Government of Telangana	Suspension of drug license for 5 days from the date of receipt of order	Order received on December 20,2023	Violation of various conditions of licences pursuant to provisions of Section 65 / Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945

Financial Impact:

There is no Financial impact. The Company is taking corrective action in this regard.

